3Chopt Investment Partners LLC Purchases New Shares in Boston Scientific Corporation $BSX

3Chopt Investment Partners LLC purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, Holdings Channel.com reports. The fund purchased 1,941 shares of the medical equipment provider’s stock, valued at approximately $208,000.

Several other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares during the period. Invesco Ltd. raised its position in Boston Scientific by 5.3% in the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider’s stock worth $1,677,124,000 after acquiring an additional 834,274 shares during the period. Goldman Sachs Group Inc. raised its position in Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after acquiring an additional 1,383,524 shares during the period. Amundi raised its position in Boston Scientific by 2.6% in the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider’s stock worth $1,212,408,000 after acquiring an additional 311,034 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Boston Scientific by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider’s stock worth $1,139,938,000 after acquiring an additional 460,580 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $95.41 on Friday. The company has a 50 day moving average of $101.98 and a 200 day moving average of $101.87. The stock has a market cap of $141.38 billion, a P/E ratio of 56.79, a P/E/G ratio of 2.34 and a beta of 0.61. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. Boston Scientific’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company’s stock, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $17,972,457 in the last three months. Insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Evercore ISI lowered their price objective on shares of Boston Scientific from $115.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday. Wells Fargo & Company boosted their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a research report on Thursday, July 24th. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. UBS Group boosted their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday, July 24th. Finally, Canaccord Genuity Group boosted their price target on shares of Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $120.71.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.